There is considerable consumer and physician interest in vitamin D as a possible therapeutic agent for a range of clinical conditions and, despite mixed evidence, the interest does not appear to lessen. Some clinicians believe that consumption of vitamin D is inadequate and, in turn, advocate vitamin D supplementation to increase serum levels of the nutrient. However, evidence concerning the role of vitamin D in health and disease is conflicting, and primary care physicians have little time to sort through the data and may find it difficult to advise their patients. To better understand the challenges that primary care physicians face regarding vitamin D, and to help inform those who provide guidance for clinical decision-making, the Office of Dietary Supplements at the National Institutes of Health, with co-sponsorship from other federal health agencies, held a conference titled The following eight questions were developed based on discussions that took place during the conference titled Vitamin D: Moving Toward Evidence-based Decision Making in Primary Care.
The following eight questions were developed based on discussions that took place during the conference titled Vitamin D: Moving Toward Evidence-based Decision Making in Primary Care. 1 
WHAT IS THE EVIDENCE FOR VITAMIN D HEALTH BENEFITS?
There is widespread agreement that vitamin D promotes bone health and, together with calcium, helps to protect older adults from bone loss. Also, there appears to be benefit from vitamin D supplementation to prevent falls in the frail elderly who are at risk for vitamin D deficiency. Whether vitamin D supplementation offers the same benefit in healthy, well-nourished older individuals is unclear. Beyond bone health and possibly fall prevention, research during the last 15 years has provided tantalizing and well-publicized suggestions that adequate vitamin D status might provide other benefits including reduced risk for cardiovascular disease, cancer, diabetes, autoimmune diseases, and infectious respiratory diseases. B Most of the research linking vitamin D to non-bone-health outcomes stems from observational studies, which identify associations, rather than randomized controlled trials. Observational studies are poor guides for therapeutic interventions because of uncontrolled confounding. B Several large trials are in progress to investigate the effects of vitamin D supplementation on outcomes such as cancer and cardiovascular disease. Results from these studies will not be available for several years, but they will help to clarify whether or not vitamin D is beneficial in ways other than bone health. The Endocrine Society agreed with the Institute of Medicine conclusions for the general population, but not for those "at risk" such as older adults, pregnant women, and dark-skinned individuals, for whom they recommended 30 ng/mL. 
WHY DO SO MANY LABORATORY REPORTS INDICATE A DEFICIENCY?
With no agreed-upon serum 25(OH)D level linked to vitamin D benefits, medical laboratories often establish cut-points based on their interpretation of the current literature. B These cut-points can vary greatly or change over time. B Clearly, the higher the cut-points selected by the laboratory, the more people are classified as deficient. B An apparent increase in the prevalence of vitamin D deficiency is explained by the use of high cut-points. B Some laboratories use a reference range from "low" to "high," and bracket the low end of the range by using a reference value established by the Institute of Medicine as the highest need (97.5%), and using as the top end of the range the reference value that demarcates the point at which the risk for harm from excess levels begins to increase (Upper Level reporting method because by definition, the low end of the range is adequate for virtually all individuals. Despite the debates and related measurement issues, serum 25(OH)D concentrations below 12 ng/mL are universally associated with deficiencies and should trigger treatment. Likely candidates for low serum 25(OH)D concentrations are the frail institutionalized elderly, because their diets may be poor and they often lack exposure to the sun.
ARE LABORATORY TESTS FOR VITAMIN D STATUS RELIABLE?
Primary care physicians may not be aware of issues surrounding the measurement of serum 25(OH)D. Medical laboratories use any of several test methods, including competitive protein binding, immunoassay, highperformance liquid chromatography, and combined highperformance liquid chromatography and mass spectrometry.
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B The sensitivity and specificity of these methods varies, both among the methods of measurement and between laboratories using the same testing method. Moreover, there is no internationally recognized reference standard. Discrepancies between methods and laboratories likely range from 10% to 20%. B Also, 25(OH)D levels may decrease in response to inflammation and acute illness (and possibly as a result of changes in the related binding protein and other carriers), potentially explaining why vitamin D status appears low when patients are sick. B It is unclear whether common laboratory reference ranges are appropriate for all ethnic groups. The bottom line is that laboratory testing of vitamin D status may misclassify individuals as vitamin D insufficient or adequate due to the variability of the assay and laboratory used, especially when the individual's value is close to the cut-point selected. B This suggests the need for caution and the consideration of other factors when individuals present with measurements very close to whatever cut-point is used.
ARE THERE RECOMMENDATIONS ABOUT SCREENING FOR VITAMIN D STATUS?
Most organizations do not recommend universal screening for vitamin D. B The US Preventive Services Task Force concluded that the benefits as well as any potential harms from vitamin D screening and early interventions cannot be determined.
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B Further more, groups such as the Endocrine Society, 4 the American Geriatrics Society, 6 the American Academy of Pediatrics, 7 
ARE THERE CONCERNS ABOUT OVER-SUPPLEMENTING WITH VITAMIN D?
There is a common misconception that vitamin D supplementation is safe at any reasonable level, or that if some is good, more may be better. B It is clear that vitamin D intakes and serum 25(OH)D must be very high-perhaps 200-400 ng/mL-to cause the classic toxicity of marked hypercalcemia and kidney and liver damage. B However, emerging observational data suggest that adverse outcomes may occur at much lower levels, such as in the 50-75 ng/mL range. These suspected adverse outcomes appear to include increases in allcause mortality and increases in the rate of heart disease and some cancers. Limited evidence suggests that African Americans may be more susceptible to these adverse effects.
Nevertheless, there is little concern about vitamin D excess at doses between 400 and 1000 IU per day. Concerns have been raised about supplementation in the range of 10,000-50,000 IU per day, which may be excessive.
IS VITAMIN D A TOPIC FOR SHARED DECISION-MAKING?
Testing for vitamin D status and potentially deciding on the use of supplements might be the subject of a conversation between the clinician and patient that includes taking into account values and preferences of the patient.
B While the many uncertainties surrounding vitamin D may make it a good candidate for shared decisionmaking in the minds of some, others argue that there are too many uncertainties to allow a meaningful conversation. As suggested by those in the latter group, clinicians have limited time to spend with their patients and there are likely other health matters more pressing than vitamin D, so the best course of action would be not to bring up the issue of vitamin D unless the patient asks or there is a clinical reason to do so.
